Benazepril Hydrochloride Tablets

1. Blood pressure reduction: This product is hydrolyzed into benazeprilat in the liver, becoming a competitive angiotensin converting enzyme inhibitor, preventing angiotensin I from converting to angiotensin II, reducing vascular resistance, reducing aldosterone secretion, and increasing plasma renin activity. Benazeprilat also inhibits the degradation of bradykinin, which also reduces vascular resistance and produces a blood pressure reduction effect. 2. Reduce cardiac load: This product dilates arteries and veins, reduces peripheral vascular resistance or cardiac afterload, reduces pulmonary capillary entrapment pressure or cardiac preload, and also reduces pulmonary vascular resistance, thereby improving cardiac output and prolonging exercise tolerance and time.

Chemical name of this product: 3-[(1-ethoxycarbonyl-3-phenyl-(1S)-propyl)amino]2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)benzazepine-1-acetic acid hydrochloride.

This product is a film-coated tablet, which appears white after removing the film coating.

1. Hypertension (can be used alone or in combination with other antihypertensive drugs such as diuretics) 2. Heart failure (can be used alone or in combination with cardiotonic diuretics).

1 Adult Dosage (1) Blood pressure reduction: For those who are not taking diuretics, the recommended initial dose is 10 mg orally once a day; for those who are already taking diuretics (except for severe and malignant hypertension), diuretics should be discontinued for 2 to 3 days before using this product. The drug should be administered in small doses and the dose should be increased carefully under observation. If blood pressure cannot be satisfactorily controlled by administration once a day, the dose can be increased or administered in two doses, and the maintenance dose can reach 20 mg to 40 mg/day. Patients with poor renal function or water or sodium deficiency should start with 5 mg once a day. (2) Heart failure: The recommended initial dose is 5 mg orally once a day. Blood pressure should be monitored during the first dose. The maintenance dose can be 5 mg to 10 mg once a day. Patients with severe heart failure require a smaller dose than those with mild to moderate heart failure. 2 There is no research data on the dosage for children.

1 Common symptoms include: headache, dizziness, fatigue, drowsiness, nausea, and cough. The most common symptoms are headache and cough. 2 Rare symptoms include: symptomatic hypotension, postural hypotension, syncope, palpitations, peripheral edema, rash, dermatitis, constipation, gastritis, anxiety, insomnia, paresthesia, arthralgia, myalgia, and asthma. Angioneurotic edema is rare.

1. Those who are allergic to benazepril or other angiotensin converting enzyme inhibitors. 2. Those with a history of angioedema. 3. Those with solitary kidney, transplanted kidney, bilateral renal artery stenosis and renal impairment.

Precautions for children: There is no research data on the safety and effectiveness of this product in children. Precautions for pregnancy and lactation: This product should not be used by pregnant women (see [Contraindications]). 1. Pregnant women Taking ACE inhibitors may cause fetal or neonatal illness or death. There have been dozens of such reports in literature around the world. The use of ACE inhibitors in the second and third trimesters of pregnancy may cause fetal and neonatal damage, including hypotension, neonatal skull deformity, anuria, reversible or irreversible renal impairment, and even death. The resulting polyhydramnios often leads to limb contractures, facial deformation, and lung dysplasia in infants. In addition, there are reports of premature birth, intrauterine growth retardation, and patent ductus arteriosus, but it is not yet certain whether these symptoms are related to the use of ACE inhibitors. The use of ACE inhibitors in early pregnancy is associated with an increased risk of congenital defects. Once pregnancy is confirmed, ACE inhibitors should be stopped immediately and the growth and development of the fetus should be monitored regularly. For women who are preparing to become pregnant, ACE inhibitors (including Lotensin) should also be avoided. Women of childbearing age should be specifically informed of the potential risks of taking ACE inhibitors (including Lotensin). The drug should be administered only after careful consideration and discussion of the relevant risks and benefits. 2. It has been found that benazepril and benazeprilat can be secreted into breast milk in lactating women, but the maximum concentration is only 0.3% in plasma. The amount of benazeprilat that can reach the infant's systemic circulation is negligible. Although it is unlikely to have adverse effects on breastfed infants, it is still not recommended to take this product during lactation. Precautions for the elderly: Elderly patients use this product in the same way as adults.

1. When used in combination with diuretics, the antihypertensive effect is enhanced, which may cause severe hypotension. Therefore, the original diuretics should be discontinued or reduced, and this product should be used at a small dose at the beginning and the dose should be adjusted gradually. 2. When used in combination with other vasodilators, it may cause hypotension. If used in combination, it should be started at a small dose. 3. When used in combination with potassium-retaining diuretics (such as spironolactone, triamterene, and amiloride), it may cause hyperkalemia. 4. When used in combination with non-steroidal anti-inflammatory analgesics, the antihypertensive effect of this product may be weakened by inhibiting prostaglandin synthesis and water and sodium retention. 5. When used in combination with other antihypertensive drugs, the antihypertensive effect is enhanced. Among them, it has a greater additive effect with drugs that cause renin release or affect sympathetic activity, and a less than additive effect when used in combination with beta-receptor blockers.

Keep away from light and store in sealed container.

10mg

36 months

Chengdu DIAO Pharmaceutical Group Co., Ltd.

• Founded in:

  1988-08-25

• Address:

  No. 26, Chuangye Road, Gaoxin Avenue, Hi-tech Zone, Chengdu

• Tax NO.:

  915101002019391454

• Registered Funds:

  728 million yuan

• Website:

  Log in to view

• Email:

  Log in to view